Lipocine Statistics

Total Valuation

Lipocine has a market cap or net worth of $15.62 million. The enterprise value is -$2.20 million.

Market Cap	15.62M
Enterprise Value	-2.20M

Important Dates

The last earnings date was Thursday, May 8, 2025, before market open.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.08% in one year.

Current Share Class	5.35M
Shares Outstanding	5.35M
Shares Change (YoY)	+1.08%
Shares Change (QoQ)	-5.88%
Owned by Insiders (%)	2.95%
Owned by Institutions (%)	9.24%
Float	5.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.77
Forward PS	3.72
PB Ratio	0.91
P/TBV Ratio	0.91
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 15.64

Current Ratio	15.64
Quick Ratio	15.31
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -24.89% and return on invested capital (ROIC) is -18.59%.

Return on Equity (ROE)	-24.89%
Return on Assets (ROA)	-17.60%
Return on Invested Capital (ROIC)	-18.59%
Return on Capital Employed (ROCE)	-33.69%
Revenue Per Employee	$229,677
Profits Per Employee	-$335,634
Employee Count	16
Asset Turnover	0.16
Inventory Turnover	n/a

Taxes

In the past 12 months, Lipocine has paid $681 in taxes.

Income Tax	681
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.11% in the last 52 weeks. The beta is 1.52, so Lipocine's price volatility has been higher than the market average.

Beta (5Y)	1.52
52-Week Price Change	-45.11%
50-Day Moving Average	3.24
200-Day Moving Average	4.26
Relative Strength Index (RSI)	38.48
Average Volume (20 Days)	17,399

Short Selling Information

The latest short interest is 70,640, so 1.32% of the outstanding shares have been sold short.

Short Interest	70,640
Short Previous Month	71,895
Short % of Shares Out	1.32%
Short % of Float	1.36%
Short Ratio (days to cover)	6.42

Income Statement

In the last 12 months, Lipocine had revenue of $3.67 million and -$5.37 million in losses. Loss per share was -$1.01.

Revenue	3.67M
Gross Profit	3.67M
Operating Income	-6.47M
Pretax Income	-8.49M
Net Income	-5.37M
EBITDA	-6.42M
EBIT	-6.47M
Loss Per Share	-$1.01

Full Income Statement

Balance Sheet

The company has $19.72 million in cash and n/a in debt, giving a net cash position of $19.72 million or $3.69 per share.

Cash & Cash Equivalents	19.72M
Total Debt	n/a
Net Cash	19.72M
Net Cash Per Share	$3.69
Equity (Book Value)	19.20M
Book Value Per Share	3.59
Working Capital	19.03M

Full Balance Sheet

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -176.00% and -146.13%.

Gross Margin	100.00%
Operating Margin	-176.00%
Pretax Margin	-146.11%
Profit Margin	-146.13%
EBITDA Margin	-174.83%
EBIT Margin	-176.00%
FCF Margin	n/a

Dividends & Yields

Lipocine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.08%
Shareholder Yield	n/a
Earnings Yield	-30.65%
FCF Yield	n/a

Analyst Forecast

The average price target for Lipocine is $10.00, which is 242.47% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	242.47%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	36.22%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.

Last Split Date	May 12, 2023
Split Type	Reverse
Split Ratio	0.0588235:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1